Premium
One‐week use of ranitidine bismuth citrate, amoxycillin and clarithromycin for the treatment of Helicobacter pylori ‐related duodenal ulcer
Author(s) -
Joseph J.Y. Sung,
Wai K. Leung,
T. K. W. Ling,
Man Yee Yung,
Francis K.L. Chan,
Y. T. Lee,
A. F. B. Cheng,
Sheng-Ying Chung
Publication year - 1998
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1046/j.1365-2036.1998.00367.x
Subject(s) - clarithromycin , medicine , omeprazole , helicobacter pylori , metronidazole , gastroenterology , ranitidine , proton pump inhibitor , ranitidine hydrochloride , amoxicillin , breath test , antibiotics , microbiology and biotechnology , biology
Background: Proton pump inhibitors have been widely used in combination with amoxycillin, clarithromycin or metronidazole for the treatment of Helicobacter pylori infection. Aim: To study the effects of 1‐week ranitidine bismuth citrate (RBC)‐based triple therapy in the treatment of H. pylori‐ related duodenal ulcers. Method: Patients with duodenal ulcers and H. pylori infection were prospectively randomized to receive either RBC with amoxycillin and clarithromycin for 1 week (RAC), or omeprazole with amoxycillin and clarithromycin for 1 week (OAC). No additional ulcer healing drug was used after the 1‐week medication. Patients were assessed for H. pylori eradication, ulcer healing and side‐effects after receiving the therapies. Results: One hundred consecutive patients were recruited to this study, with 50 patients randomized to each treatment group. In the intention‐to‐treat analysis, duodenal ulcers were completely healed in 45 (90%) patients in the RAC group and 43 (89.6%) in the OAC group ( P = 1.0). H. pylori eradication was confirmed in 47 (94%) in the RAC group and 42 (87.5%) in the OAC group ( P = 0.31). There was no significant difference in the severity of side‐effects experienced by the two treatment groups. Conclusion: One‐week RBC‐based triple therapy is an effective treatment for H. pylori ‐related duodenal ulcers. The therapeutic effects are comparable to a 1‐week course of proton pump inhibitor‐based triple therapy.